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Deregulation of the Ras/Raf/MEK/extracellular signal-regulated kinase pathway is a com-
mon event in childhood acute lymphoblastic leukemia and is caused by point mutation,
gene deletion, and chromosomal translocation of a vast array of gene types, highlighting
its importance in leukemia biology. Pathway activation can be therapeutically exploited and
may guide new therapies needed for relapsed acute lymphoblastic leukemia and other high
risk subgroups.
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THE Ras/Raf/MEK/ERK PATHWAY
The mitogen-activated protein kinase (MAPK) cascade is a key
signaling pathway that regulates diverse cellular functions includ-
ing cell proliferation, survival, differentiation, angiogenesis, and
migration (1–4). Classical activation is initiated by ligand bind-
ing to receptor tyrosine kinases (RTK) at the cell surface and
via Ras, then Raf, then MEK (mitogen-activated protein kinase
kinase), culminates in the regulation of gene transcription in
the nucleus by the last pathway component, extracellular signal-
regulated kinase (ERK). Since the pathway regulates many cellular
functions that are classic hallmarks of cancer, it is not surpris-
ing that it is deregulated in numerous cancer types, including
childhood acute lymphoblastic leukemia (ALL).
The core of the signaling pathway comprises three dual-specific
protein kinases Raf, MEK, ERK, and the G-protein Ras. The
RAS family contains three genes HRAS, NRAS, and KRAS that
encode 21 kDa proteins. The KRAS transcript undergoes alter-
nate splicing thus resulting in four Ras protein isoforms (HRas,
NRas, KRas4A, KRas4B). Ras proteins are monomeric membrane-
associated GTPases, which communicate binary on or off messages
to downstream effector proteins by cycling between an active GTP
bound and inactive GDP bound state. Ras activation is catalyzed
by guanine nucleotide exchange factors (GEFs), such as son of
sevenless (SOS), which displace GDP and allow GTP to preferen-
tially occupy the vacant nucleotide binding site due to its relative
abundance in the cytoplasm. Ras proteins exhibit intrinsic low-
level hydrolytic activity and are negatively regulated by GTPase
activating proteins (GAPs) such as neurofibromin (Nf1), which
stimulate GTP hydrolysis and formation of inactive RAS–GDP
(Figure 1).
All four isoforms of Ras are widely expressed, although the
relative degree of expression varies between tissues and devel-
opmental stage. They are highly homologous with differences in
sequence largely limited to the C-terminal hypervariable region.
Ras proteins must be localized to the inner surface of the plasma
membrane to interact with upstream activators and downstream
effectors to allow correct signaling. The immature Ras mole-
cule has a hydrophilic globular structure that requires a series
of post-translational modifications. These include addition of a
15-carbon farnesyl isoprenoid lipid at the C terminus that greatly
improves the affinity of Ras for plasma membranes and palmi-
toylation that mediates vesicular transport to the cell surface.
Palmitoylation is a reversible modification liable to degeneration
creating a palmitoylation–depalmitoylation cycle in which Ras is
recycled between membrane and Golgi. An exception to this is
KRas4B, which translocates directly to the plasma membrane after
farnesylation in a process postulated to involve chaperone proteins.
Activation of a RTK stimulates autophosphorylation of its
intracellular SH2 domain that recruits growth factor receptor-
bound protein 2 (Grb2), which serves to localize GEFs to the mem-
brane to initiate Ras to exchange GDP for GTP. Ras then induces
Raf activation by phosphorylation at specific serine residues result-
ing in the formation of Raf homo or hetero dimers. All four
isoforms of Ras are able to activate all three members of the
Raf gene family (A Raf, B Raf, Raf-1). Raf subsequently acti-
vates MEK1/2, which display restricted substrate specificity for
ERK1/2. ERK is a potent kinase with a diverse range of both nuclear
and cytoplasmic substrates. It regulates gene expression by phos-
phorylating numerous transcription factors including Elk1. The
Ras/Raf/MEK/ERK pathway (now abbreviated to Ras pathway) is
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FIGURE 1 | Regulation of Ras activity.
also implicated in the regulation of apoptosis by enhancing gene
expression of pro-survival Bcl-2 family proteins and targeting anti-
apoptotic proteins for proteasomal degradation (5). In addition
to Raf/MEK/ERK, Ras generates signal output via numerous other
effector pathways, including PI3K/Akt/mTOR and RalGEF/RAL.
Cross talk between Ras and the PI3K pathway is of particular
importance given their prominent role in the regulation of cell
growth and survival (2, 6–8).
MECHANISMS OF Ras PATHWAY ACTIVATION IN ALL
Somatic mutation of genes, which activate the Ras pathway are
recurrently found in ALL and include integral components of the
pathway, upstream activators, and regulatory proteins and include
NRAS, KRAS, BRAF, FMS-related tyrosine kinase 3 (FLT3), pro-
tein tyrosine phosphatase, non-receptor type 11 (PTPN11), casitas
B lineage lymphoma (CBL), and NF1. An overview is shown in
Figure 2.
NRAS/KRAS (NEUROBLASTOMA RAS VIRAL ONCOGENE
HOMOLOG/KIRSTEN RAT SARCOMA VIRAL ONCOGENE HOMOLOG)
Mutations in NRAS and KRAS are highly prevalent in ALL (9–25).
NRAS mutations are more common in ALL and in other hema-
tological malignancies, contrasting with epithelial malignancies
where KRAS mutations predominate (2, 4). HRAS mutations are
rare outside the context of urinary tract, cervical, and salivary
gland tumors and are not found at a significant level in hemato-
logical cancers. The vast majority of mutations in NRAS/KRAS
cluster within hotspots at codons 12, 13, and 61 and dramati-
cally reduce the rate of GTP hydrolysis by inhibiting interaction
with GAPs and thus are locked in the active GTP bound, lead-
ing to constitutive activation. In the largest study to date, 90% of
NRAS/KRAS mutations identified in ALL were located within exon
2, with the most commonly occurring genetic aberration involv-
ing a G:C to A:T transition (9). While early studies in childhood
ALL reported an incidence below 10%, more contemporary stud-
ies consistently demonstrate mutations in 15–30% of ALL cases:
more in B lineage disease, a preponderance in hyperdiploidy and a
rarity in TEL–AML1 subgroups (10, 15, 16, 19). Higher incidences
FIGURE 2 | Mutations activating the Ras pathway in ALL and potential
therapeutic targeting. Components of the pathway that are mutated in
ALL are in red.
may reflect the use of mutation screening methods such as dena-
turing high performance liquid chromatography, which are more
sensitive than Sanger sequencing and can detect mutations present
in only 12–25% of cells (15). Clinical samples harboring NRAS or
KRAS mutations invariably demonstrate increased levels of phos-
phorylated ERK, indicative of activation of the Ras pathway but to
varying degrees (15, 26).
FMS-RELATED TYROSINE KINASE 3
FMS-related tyrosine kinase 3 is an RTK that is preferentially
expressed on the surface of hematopoietic progenitors with its
ligand is derived from neighboring bone marrow stroma cells.
It has been extensively studied in the context of acute myeloid
leukemia (AML) in which mutations occur in approximately a
third of cases (27). FLT3 mutations occur at lower frequency
in ALL, being reported in around 2–9% of cases, and again are
often associated with hyperdiploidy (15, 19, 28–34). Mutations are
broadly localized to two domains: missense substitutions or small
in-frame deletions occur within the tyrosine kinase domain while
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in-frame insertion or deletions affect the juxta-membrane region
of the protein, which has an autoinhibitory function. The latter
mutations often affect a 10 amino acid stretch between Tyr 589
and Tyr 599 that has been functionally shown to cause activation
if disrupted (35). Mutations cause constitutive activation of Flt3,
hypersignaling of the Ras pathway and confer ligand-independent
proliferation in vitro, confirming their functional significance (36,
37). Interestingly, in MLL-rearranged ALL, Flt3 is often consti-
tutively activated because of high level expression rather than
mutation (38, 39). Other RTKs implicated in deregulated Ras
signaling include Mer, which has been shown to be aberrantly
expressed in a third of Pre B ALL (40).
PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11
Shp2 encoded by thePTPN11 gene is a member of the protein tyro-
sine phosphatase family and is highly expressed in hematopoietic
cells. Despite its role in protein dephosphorylation, Shp2 plays
an overall positive role on cell signaling pathways, including Ras
and JAK–STAT pathways. While the mechanism is not clear, pos-
tulated targets of Shp2 include Ras GAP binding sites on RTKs
or key tyrosyl residues on Sprouty proteins, which inhibit the
pathway and more recent evidence implicates a role in increas-
ing production of reactive oxygen species, which hypersensitizes
cytokine signaling (41). Somatic mutations of PTPN11 are com-
mon in juvenile myelomonocytic leukemia where they occur in
around 35% of cases but are also found in ALL at frequencies
between 2 and 10% (10, 14, 15, 19, 42). Mutations are usually
heterozygote, missense, gain of function mutations sited in the
SH2 or phosphatase regions of the protein. In mouse models,
PTPN11 mutations cause a myeloproliferative disorder (MPD)
but a more recent study showed that the PTPN11 E76K mutation
was clearly sufficient to induce acute leukemia and this residue is
commonly mutated in ALL (43). The E76K mice leukemias were
associated with centrosome amplification and aneuploidy, which
is highly relevant given the predominance of PTPN11 mutations
in hyperdiploid ALL cases.
BRAF (V-RAF MURINE SARCOMA VIRAL ONCOGENE HOMOLOG B)
Activating mutations of the serine threonine kinase, BRAF, were
first identified in melanoma and cluster at the hot spot V600E site.
About two-thirds of melanoma patients have BRAF mutations
(44). A first investigation of BRAF mutations in a small Swiss
population of pediatric ALL patients found an incidence of 20%,
with about half of patients bearing a L597Q mutation (12). This
specific mutation was later shown to be transforming in vitro (45).
However, mutational screening of larger cohorts of infant, child-
hood B and T lineage ALL have found only rare instances of BRAF
mutations, with the classic V600E mutation seen only once (15, 24,
25, 46, 47). In early thymocyte precursor (ETP) ALL, focal ampli-
fication of BRAF was found in one patient, thus amplification of
BRAF rather than mutation may be an alternative mechanism of
activation (25).
CASITAS B LINEAGE LYMPHOMA
A more recently reported gene family implicated in Ras pathway
activation is the CBL proteins, a highly conserved family of RING
finger ubiquitin E3 ligases that target a variety of RTKs for degra-
dation. Screening of CBL in an unselected cohort of ALL patients
identified somatic mutations in 1–2% of cases (48, 49). Muta-
tions have also been reported in T ALL and infant ALL and are
often associated with acquired uniparental disomy at theCBL gene
locus, resulting in a homozygous mutant state (49–51). Functional
analyses have shown mutations to be associated with stabilization
of RTK receptors in an active state, constitutive activation of the
Ras pathway, and cellular sensitivity to MEK inhibitor (MEKi)
treatment.
OTHER
The NF1 gene encodes neurofibromin (Nf1), a GAP that inhibits
Ras signaling by stimulating hydrolysis of active RAS–GTP into
inactive RAS–GDP. Inactivation of Nf1 by gene microdeletion
and mutation have been found at low frequency in both T and
B lineage ALL (52, 53). In mouse models, somatic inactivation of
NF1 in hematopoietic cells induces an MPD (54). Chromosomal
translocation events, including BCR/ABL and those involving the
MLL locus, also cause constitutive activation of the Ras pathway
(55–57).
The diverse routes exploited by leukemia cells to activate the
Ras pathway highlights the importance of the pathway in leuke-
mogenesis and progression. Several studies report on the mutual
exclusivity of Ras pathway mutations in that few patients appear
to have more than one mutation, suggesting that one pathway
activating event precludes the need for a second (10, 14, 15, 19).
However, this finding is not universal and it may be that more
sensitive mutation detection methodologies such as high cover-
age next generation sequencing and allele-specific PCR will reveal
more co-existing Ras pathway mutations within one leukemia, but
it is likely that they are present in separate cell populations (24).
ARE Ras PATHWAY MUTATIONS AN INITIATING OR
SECONDARY EVENT?
There are various inherited developmental disorders caused by
germline mutations in components of the Ras signaling pathway,
so called Rasopathies that have an increased risk of hematological
malignancies, including ALL (58). In addition, there is mounting
evidence from a variety of mouse models that genes that activate
the Ras pathway includingNRAS/KRAS,NF1, andPTPN11 are ini-
tiating events in the development of ALL, giving rise to both B and
T lineage ALL (43, 59–64). The majority of studies have focused
on KRAS and NRAS mutant forms and suggest that oncogenic
Ras alone is insufficient to drive leukemogenesis and cooperat-
ing genetic events are necessary for full-blown leukemia. In the
context of T ALL, NOTCH mutations are often this cooperating
genetic event (59, 63, 65, 66). Hematopoietic stem/progenitor cell
populations from KRASG12D mice show similar basal levels of
phosphorylated ERK relative to wild type but generate an exag-
gerated response to growth factor stimulation suggesting mutant
Ras renders them more sensitive to mitogenic signals rather than
causing unbridled saturation of the pathway (67). A recent pub-
lication by Li et al. shows that in hematopoietic stem cells, NRAS
mutations have a bimodal effect, increasing the likelihood of cell
division in some cells and decreasing it in others, thus generating
an expanding, more rapidly dividing cell population and another
with long-term self-renewal (68). This may allow mutated cells to
have long-term clonal dominance over wild type cells.
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However, there are several lines of evidence in primary sam-
ples suggesting that Ras pathway mutations occur as a second,
cooperative genetic “hit” as opposed to the initiating event, at
least in some patients. For example, there are several reports of
mutations existing in only a minor population of leukemia cells
at diagnosis and a recent report suggests that KRAS mutations
are commonly found at very low level in a significant number
of diagnostic ALL who were genotyped as Ras pathway wild type
by standard mutation screening (10, 15, 26). PTPN11 and RAS
mutations have been shown to be present at diagnosis of ALL
but not at relapse, suggesting a secondary role (42, 69). In MLL-
rearranged ALL, oncogenic KRAS has itself been shown to act as a
cooperative lesion and the introduction of KRAS mutations into
MLL/AF4 transgenic mice results in a more aggressive leukemic
phenotype, which more closely mirrors the human equivalent
(70, 71). In addition, Wiemels et al. used allele-specific PCR to
backtrack KRAS mutations present in diagnostic hyperdiploid
ALL in blood derived from matched neonatal mono-spots (16).
These experiments failed to detect the presence of KRAS muta-
tion prenatally but detected the clonal immunoglobulin heavy
chain rearrangement specific to the hyperdiploid clone. This sug-
gests a temporal relationship in which KRAS mutation occurs
subsequent to the development of the hyperdiploid clone. Taken
together, the evidence suggests that similar to AML, Ras pathway
activating mutations may act as an early/initiating or cooperating
events acquired during disease progression and clearly may have
implications for therapies targeting the pathway.
The clear role of NRAS and KRAS mutations in the pathogen-
esis of many cancer types has prompted both epidemiological and
animal studies that examine exposure to certain chemical muta-
genic substances with the presence of specific mutations. In the
context of ALL, a study by Shu et al. showed that parental occu-
pational exposure to hydrocarbons and mind-altering drugs was
related to specific RAS mutations in ALL (11). There was also an
association with younger children, which may suggest a precon-
ception or in utero origin of the mutation. Another study identified
NRAS and KRAS mutations to be associated with a variety of
maternal and paternal exposures but these associations were not
corroborated in a subsequent larger study (13, 16).
Ras PATHWAY MUTATIONS IN NEWLY DIAGNOSED ALL
While early studies focused solely on mutations in NRAS and
KRAS, more comprehensive screens with inclusion of additional
genes impacting on the pathway, including PTPN11, FLT3, and
CBL, report mutations in up to 35% of newly diagnosed ALL,
with a predominance in B lineage ALL (9–11, 13, 14, 16, 18–20,
32, 72–74). Table 1 summarizes the largest studies to date and
Figure 3 shows the frequencies of mutated genes identified in a
UK diagnostic cohort (15, 48).
While one early study demonstrated a significantly higher rate
of hematological relapse and a trend toward reduced complete
remission rates amongst cases harboring NRAS mutations, the
association between RAS mutation and adverse outcome has not
been replicated in more recent studies, raising the possibility that
contemporary chemotherapeutic regimens have negated the effect
(9, 12, 18, 74). In the largest investigation of the prognostic signif-
icance of NRAS and KRAS mutation that included 870 patients
enrolled on an US study, mutation status had no discernable effect
on event free survival, disease free survival, or overall survival and
there was no relationship between RAS mutations and high risk
clinical features (9). A smaller UK study did show a statistically
significant association with Ras pathway mutation and some high
risk features such as higher presenting white cell count but not
others, such as day 8 bone marrow clearance (15). In the US study,
when specific RAS mutations were compared individually, muta-
tions in exon 2 of the KRAS gene were associated with younger
age at presentation and were less likely to occur in the context of
B cell disease when compared to mutations at other locations (9).
Mutations in the Ras pathway clearly show a strong correla-
tion with specific cytogenetic subgroups of ALL and are prevalent
in both very poor and very good risk cytogenetic groups, which
may neutralize any effect on prognosis when a patient cohort is
analyzed as a whole. For example, Ras pathway mutations are con-
sistently associated with high hyperdiploidy, which represents a
third of all newly diagnosed children and confers a very favorable
prognosis (13, 15, 16, 19, 32, 72, 76). Reported incidences of Ras
pathway mutations in this subgroup range from 24% to almost
60%, with a large study reporting mutations in 30% compared
to 10% in non-hyperdiploid cases (16). They also occur at high
frequency in the context of hypodiploid ALL (23). Hypodiploidy
(<45 chromosomes) occurs in around 5% of cALL cases and is
associated with a very poor prognosis (77). Hypodiploidy can
be further divided by karyotype into three distinct groups, near-
haploid (23–29 chromosomes), low hypodiploidy (33–39 chro-
mosomes), and high hypodiploidy (42–45 chromosomes). More
than two-thirds of near-haploid cases feature mutations predicted
to result in aberrant Ras signaling, in particular intragenic dele-
tion of NF1 (23). Enhanced signaling has been demonstrated in
low hypodiploid cases in the absence of known canonical Ras path-
way mutations, suggesting that additional mechanisms of pathway
activation remain to be identified in this subgroup (23). One pos-
sible mechanism is the deregulated expression of a microRNA,
MiR335 that targets and regulates levels of ERK2 (78). The high
prevalence of pathway mutations in aneuploid leukemias is notable
and there is evidence of a possible link between deregulated sig-
naling through the Ras pathway and chromosomal instability (79).
Ras pathway mutations have also been identified at high incidence
in cases defined as “high risk” and also in the very aggressive,
ETP ALL (24, 25). In addition, poor risk chromosomal transloca-
tions, including BCR/ABL and those involving the MLL locus are
associated with constitutive activation of the Ras pathway (55–57).
Interestingly, Ras pathway mutations are rare in the ETV6–RUNX1
cytogenetic subgroup (10, 15).
Recent investigations have questioned the impact of RAS muta-
tion and prognostic significance within the context of specific
cytogenetic groups. For example, in MLL-rearranged infant ALL
in whom NRAS/KRAS mutations are present in 24–50% of cases,
mutations were shown to be an independent prognostic factor
associated with an extremely poor outcome, with a 5-year event
free survival rates of 0.0% forRAS mutated compared to 32.7% for
RAS wildtype (47, 75). Mutations were also shown to be associated
with a higher presenting white blood cell count and mutated pri-
mary cells were more resistant to glucocorticoids in vitro (47).
However, a small study, which focused on hyperdiploid ALL
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FIGURE 3 | Pie chart of the frequency of Ras pathway mutations in an
unselected cohort of 180 UK diagnostic ALL [data from Ref. (15, 48)].
showed no influence of Ras pathway mutation on prognosis (19).
Large mutation screening studies of contemporary childhood ALL
trials are currently underway and will define whether Ras pathway
status has prognostic relevance and if it can enhance current risk
stratification strategies.
Ras PATHWAY MUTATIONS IN RELAPSED ALL
Mutations in the Ras pathway are common in relapsed cALL,
occurring in between 25 and 39% of B lineage cases (15, 26, 69). In
the largest study to date, which focused on children with B lineage
ALL treated on the ALL-REZ BFM 2002 trial, the presence of Ras
pathway mutations was associated with high risk features such as
early relapse. For NRAS/KRAS mutations, there was a greater pro-
portion of patients with on-treatment relapse, CNS involvement,
and chemo-resistant disease, as evidenced by reduced cytological
remission rates (26). However, this did not translate into a signifi-
cant difference in event free survival. The cytogenetic associations
seen in diagnostic cases were mirrored at relapse, with a prepon-
derance of pathway mutations in cases with hyperdiploidy and a
relative paucity in TEL–AML1.
An intriguing phenomenon seen in several studies is the find-
ing that matched diagnostic samples, when compared to relapse
with known Ras pathway mutations, are frequently wild type by
standard mutation detection screening methodologies, but more
sensitive assays reveal a minority sub-clone of cells with the same
mutation (15, 26, 72). Similar backtracking studies for antigen
receptor or copy number lesions dominating at relapse have also
identified low level clones within diagnostic samples in the major-
ity of patients (80–82). These observations give insight into the
biology of relapse in ALL and in the case of Ras pathway muta-
tions may have therapeutic implications. One model of relapse
suggests that resistant leukemic cells preexist by chance as a minor-
ity sub-clonal population at diagnosis, evade the cytotoxic effects
of chemotherapy, and go on to propagate disease as the dominant
relapse clone. In the second, there is therapy-induced acquired
resistance that drives the acquisition of de novo mutations and
clonal evolution. These models are not mutually exclusive and
both may be needed for cells to acquire total resistance to the
multi-drug chemotherapeutic barrage used in ALL.
The expansion of a pre-existing mutated RAS sub-clone at
relapse suggests that the former model plays a role in relapse and
that mutations must confer a degree of resistance to therapy. This
hypothesis is supported by in vitro studies in which activation of
the Ras pathway in hematopoietic cells is associated with resis-
tance to glucocorticoids and anthracyclines, key drugs used in
ALL therapy (47, 83, 84). Resistance is mediated by transcriptional
influences on ERK target proteins as well as those regulating the
apoptotic regulatory machinery, e.g., Bim. In one anecdotal case
with a very high level of minimal residual disease (MRD) at the
end of induction, two different KRAS-mutated clones were identi-
fied at low level in the diagnostic sample and were enriched during
induction therapy to the extent that all of the MRD cells boreKRAS
mutations (26). Such cases may benefit from therapies targeting
the Ras pathway to eradicate MRD. Importantly, in the same study,
low level KRAS mutations were shown to be relatively common
in a diagnostic cohort of long-term survivors and are clearly a
common clonal event during leukemogenesis that does not neces-
sarily herald relapse. Clearly, other factors must determine survival
of these low-level mutated clones during treatment. Importantly
Ras pathway mutations found at diagnosis have been shown to
be absent at relapse in some patients (42, 69). Whole genome
analyses of presentation, MRD, and relapse trios may shed light
on the relative contribution of the two models in the biology of
relapse and the possible role of MRD-directed therapy to avert
relapse.
THE Ras/Raf/MEK/ERK PATHWAY AS A THERAPEUTIC
TARGET
Deregulation of the Ras pathway is common across cancer types
and thus an attractive target for therapeutic inhibition and such
novel therapies may play a role in improving outcome for high risk
ALL. Numerous therapeutic strategies targeting the Ras pathway
are currently being evaluated in clinical trials.
The Ras protein itself has proved challenging to inhibit directly,
although a very recent study reported on the development of
a small molecule inhibitor, which specifically decreased viabil-
ity and induced apoptosis of lung cancer cell lines expressing
KRAS G12C, but had no effect on wild type cells or those
bearing other KRAS mutations. This important drug develop-
ment milestone will facilitate the development of other specific
mutant inhibitors (85). Early drugs were aimed at disrupting
Ras post-translational processing, principally inhibitors of farne-
syltransferase (FTase). One of these, Tipifarnib (R-115777) is a
competitive, non-peptidomimetic FTase inhibitor, which showed
in vitro activity in B and more so in T lineage ALL. However, the
small number of RAS mutant positive samples precluded statistical
analysis of mutational status on treatment response (86). Phase I
clinical trials of Tipifarnib in relapsed or refractory acute leukemia
in adults showed some clinical and biological activity in terms of
p-ERK inhibition, but the trial included a small number of adult
ALL patients, all of which demonstrated disease progression within
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7–21 days (87). Dose limiting toxicities included ataxia, confu-
sion, and dysarthria. Targeting FTase is a less than perfect strategy
in disrupting Ras pathway signaling as when FTase is inhibited,
Nras and Kras can undergo alternate post-translational process-
ing by geranylgeranyltransferase, which allows the crucial cellular
trafficking of Ras proteins to continue (88). FTase inhibitors also
target a wide variety of other CAAX motif containing peptides and
therefore Ras-independent modes of action probably account for
the marginal benefit derived in other cancers.
The restricted substrate specificity of MEK1/2 for its sole
substrate ERK1/2 has prompted the development of inhibitors
of MEK, since one would expect them to be associated with
less “off target” activity and inhibit the pathway regardless of
the mechanism of upstream activation. There are a number
of MEKi in advanced stages of clinical trial including Trame-
tinib (GSK1120212), Pimasertib (MSC1936369B), and Selume-
tinib (AZD6244, ARRY-142886) (89–92). Selumetinib is a potent,
selective, allosteric inhibitor of MEK1/2, which has reached Phase
II clinical trials in a range of solid cancers, has a favorable toxic-
ity profile and has demonstrated anti-tumor activity. In general,
sensitivity to MEKi is enhanced in tumor cells harboring acti-
vating Ras pathway mutations, including ALL cells although this
is not universal (15, 48, 66, 92–94). Initial in vivo testing of
Selumetinib against mice xenograft models of pediatric B cell
ALL showed no significant activity, but RAS mutational status
and pathway activation were not assessed (95). However, a recent
study clearly demonstrated differential sensitivity in ALL blasts
in vitro, with GI50 values being significantly lower in Ras path-
way positive cells (mean 250 nM) compared to those that were
negative (mean 68µM). These primary cells included NRAS,
KRAS, and FLT3/CBL mutants. These in vitro data were repli-
cated in vivo using NRAS and KRAS mutant ALL primagrafts
and pharmacodynamic assessments showed inhibition of p-ERK
and induction of apoptosis. Histological analysis of post-mortem
brains found extensive meningeal leukemic infiltration in con-
trol vehicle treated, but not Selumetinib-treated mice, suggesting
that this drug may eradicate CNS ALL. Some activity has also
been demonstrated in vivo for KRAS-mutated T ALL with the
MEKi, PD0325901 (66). However, similar studies in RAS-mutated
hypodiploid ALL showed no activity of MEKi but activity of
PI3K inhibitors (23). MEK inhibition has also been studied in
NF1-deficient mice (64). Bi-allelic inactivation of NF1 induces
an MPD, which can be progressed to AML using retro-viral
mutagenesis to induce secondary genetic aberrations. While the
initial MPD was relatively resistant to MEK inhibition, the NF1-
deficient leukemias were significantly more sensitive, suggesting
that cooperating mutations render them highly dependent on Ras
signaling (64).
An interesting study has teased apart the relative importance of
Raf/MEK/ERK and PI3K/Akt/mTOR pathways in a mouse model
of T lineage ALL and shown that both effector pathways are
drivers of aberrant growth initiated by KRAS G12D (96). Thus,
combining inhibitors of both pathways may be an effective thera-
peutic strategy and indeed significant synergy has been shown in
solid tumors (97, 98). However, in Ras-mutated primary B lineage
ALLs, differential activation of the Ras but not the PI3K/Akt path-
way is seen (J. Irving, unpublished observations). Nonetheless,
as evidenced by imatinib and BCR/ABL positive ALL, targeted
therapies are likely to have maximal therapeutic benefit in com-
bination (99). For MEKi, synergism has been demonstrated for
PI3K/Akt inhibitors, dexamethasone, Nutlin-3a, which induces
the MDM2-p53 axis, and the Bcl-2 and Bcl-x(L) inhibitor, Navito-
clax (ABT263) (78, 100–102). In AML cells, enhanced cytotoxicity
was achieved in vitro when MEKi were used in combination with
Nutlin-3a and PI3K/Akt inhibitors and was related to changes in
the relative balance of proapoptotic and anti-apoptotic Bcl-2 fam-
ily proteins (102, 103). Importantly, standard chemotherapeutic
drugs can activate the Ras pathway and contribute to drug resis-
tance, thus MEKi may have potential relevance in Ras pathway
induced as well as constitutively activated ALLs (104).
Other potential drugs include Raf inhibitors, specifically Braf
inhibitors,given their identification in some ALL patients. For chil-
dren with FLT3 mutations, small molecule inhibitors of Flt3 may
offer clinical benefit and there are several multi-targeted agents
in clinical trial including Lestaurtinib, Sorafenib, and AT9283.
Promising preclinical data of Flt3 inhibitors in MLL-rearranged
ALL have prompted a Phase III trial in which newly diagnosed
infants are randomized to receive combination chemotherapy plus
or minus Lestaurtinib (39, 105). The results of this trial are not
expected until 2018. Recent evidence also suggests that direct tar-
geting of mutant PTPN11 may be possible. A naturally occurring
compound, cryptotanshinone, used to treat cardiovascular disease
in Asian countries, has been shown to inhibit Shp2 and preclin-
ical studies found that mouse myeloid progenitors and primary
leukemia cells bearing the activating PTPN11 E76K mutation were
sensitive to this inhibitor (106). In addition, there is increased
mitochondrial aerobic metabolism and cytokine hypersensitivity
associated with PTPN11 mutations, which can be partially cor-
rected with antioxidants in mutant progenitor cells, suggesting
this may be another possible therapeutic approach (41).
Intriguingly, targeting mutated Ras may also be possible with
more standard chemotherapeutic agents. Early in vitro studies
suggested that Ras-mutated cancer cells may be more sensitive to
certain drugs, particularly the nucleoside analog cytarabine. These
observations have been confirmed in the clinic, with Ras mutant
positive AML patients responding significantly better to high-dose
cytarabine (107–111). In the largest study to date, Ras-mutated
AML patients receiving high-dose cytarabine during consolida-
tion had a 10-year cumulative relapse incidence of 45% compared
to 68% for wild type RAS patients and in the low dose cytarabine
arm, comparative figures were 100 versus 80%, respectively (109).
The mechanism underlying this preferential sensitivity appears
to be mutant Ras synergizing with cytarabine to activate DNA
damage checkpoints and via p53 results in increased differentia-
tion and an associated reduction in clonogenicity (112). Similar
investigations in childhood ALL trials have not been performed to
date.
SUMMARY
Ras pathway activation is common in ALL and is caused by point
mutation, gene deletion, and chromosomal translocation of a vast
array of gene types, including GTPases, RTKs, phosphatases, and
ubiquitin ligases, emphasizing its importance in leukemia biology.
Pathway activation can be therapeutically exploited and may define
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new therapies needed for relapsed ALL and given its high preva-
lence may offer clinical benefit for a significant number of children.
Such therapies may also be used upfront for high risk subgroups.
One of the most promising targeted agents, a MEKi, has shown
activity in vivo as a single agent in Ras pathway-activated ALL,
however, maximal therapeutic benefit is likely to be in combina-
tion with other drugs. Clinical trials of MEK inhibitors in multiple
relapsed ALL are planned.
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